14 / 32
Hoyle, et al. Effects of AA + P in high and
low risk mHSPC
Hypotesis:
Do “low risk “ mHNPC patients benefit from AA + P + ADT?
Methods:
1. Retrospectively stratified M1 Stampede “Abiraterone comparison” patients into high/low risk, blinded to treatment arm:
1. Primary stratification as per Latitude criteria
2. Exploratory stratification as per Chaarted criteria
2. Analyse “risk” and “volume” base data against multiple measured endpoints
Patient selection
Standard of care (SOC) was ADT.
Population
Number
(%)
LATTITUDE low 428 (47.5)
LATTITUDE high 473 (52.5)
CHAARTED low 402 (44.6)
CHAARTED high 499 (55.4)
Inclusion criteria (n=1917)
•
Metastatic disease (de-novo or previous radical treatment
•
Randomisation into STAMPEDE within UK
•
Nov 2011 and Jan 2014
•
ADT or ADT + AA + P
Included STAMPEDE M1 patients
(n=990)
SOC-only
n=497
Excluded
(n=45)
Missing Gleason score n=12
Unobtained bone imaging n=24
Unconventional bone imaging n=9
Excluded
(n=44)
Missing Gleason score n=22
Unobtained bone imaging n=17
Unconventional bone imaging n=5
Not Evaluated (n=927)
Non-metastatic (M0) patients
(n=914)
Or
Randomized in Switzerland
(n=13)
SOC
(n=452)
SOC + ADT + AA + P
n=493
SOC + ADT + AA + P
(n=449)
Hoyle, et al. Effects of AA + P in high and
low risk mHSPC
Hypotesis:
Do “low risk “ mHNPC patients benefit from AA + P + ADT?
Methods:
1. Retrospectively stratified M1 Stampede “Abiraterone comparison” patients into high/low risk, blinded to treatment
1. Primary stratification as per Latitude criteria
2. Exploratory stratification as per Chaarted criteria
2. Analyse “risk” and “volume” base data against multiple
asured endpoints
Hoyle AP, et al. Ann Oncol 2018;29(Suppl 8):LBA4.
Patient selection
Standard of care (SOC) was ADT.
Population
N
(
LATTITUDE low 4
LATTITUDE high 4
CHAARTED low 4
CHAARTED high 4
Inclusion criteria (n=1917)
•
Metastatic disease (de-novo or previous radical treatment
•
Randomisation into STAMPEDE within UK
•
Nov 2011 and Jan 2014
•
ADT or ADT + AA + P
Included STAMPEDE M1 patients
(n=990)
SOC-only
n=497
Excluded
(n=45)
Missing Gleason score n=12
Unobtained bone imaging n=24
Unconventional bone imaging n=9
Excluded
(n=44)
Missing Gleason score n=22
Unobtained bone imaging n=17
Unconventional bone imaging n=5
Not Evaluated (n=927)
Non-metastatic (M0) patients
(n=914)
Or
Randomized in Switzerland
(n=13)
SOC
(n=452)
SOC + ADT + AA + P
n=493
SOC + ADT + AA + P
(n=449)